Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapy.

Louis, Edouard;Bossuyt, Peter;Colard, Arnaud;Nakad, Antoine;Van Gassen, Geert;et.al.
(2025) Dig Liver dis:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver — Vol. 57, n° 3, p. 707-715 (2025)

Files

LouisEDigLiverDis2025.pdf
  • Open Access
  • Adobe PDF
  • 831.13 KB
Download

Details

Authors
  • Louis, Edouard
    Author
  • Bossuyt, Peter
    Author
  • Colard, Arnaud
    Author
  • Nakad, Antoine
    Author
  • Cremer, AnnelineUCLouvain
    Author
  • Setakhr, VidaUCLouvain
    Author
  • Vijverman, AnneUCLouvain
    Author
  • Van Gassen, Geert
    Author
Show more
Abstract
Fatigue is common among patients with inflammatory bowel diseases (IBDs) and is associated with decreased quality of life (QoL). Describe fatigue evolution and identify factors associated with fatigue outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) initiating biologic treatment. Data from adult Belgian patients with UC or CD enrolled in a prospective real-world study were utilized. Fatigue and QoL were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Short Inflammatory Bowel Disease Questionnaire, respectively. Factors associated with fatigue outcomes were assessed using multivariate regression. 465 patients were included: 174 with UC and 291 with CD. Average FACIT-F scores indicated improvements in fatigue after 6 months, before stabilizing. A higher probability of fatigue disappearance was associated with clinical remission and was more likely in patients with UC than CD. Patients achieving clinical remission had lower probability of fatigue. Patients with fatigue improvements experienced greater QoL improvements than patients with fatigue persistence. Real-world findings suggest fatigue partly improves in the first 6 months of biologic treatment. Clinical remission was associated with greater probability of fatigue disappearance and lower likelihood of fatigue persistence. Further research into factors associated with fatigue in patients with IBD is warranted.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Louis, E., Bossuyt, P., Colard, A., Nakad, A., Baert, D., Mana, F., Caenepeel, P., Branden, S. V., Vermeire, S., D’Heygere, F., Strubbe, B., Cremer, A., Setakhr, V., Baert, F., Vijverman, A., Coenegrachts, J.-L., Flamme, F., Hantson, A., Zhou, J., & Van Gassen, G. (2025). Change in fatigue in patients with ulcerative colitis or Crohn’s disease initiating biologic therapy. Dig Liver dis:official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 57(3), 707-715. https://doi.org/10.1016/j.dld.2024.12.011 (Original work published 2025)